{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:51:18Z","timestamp":1791363078432,"version":"4.3.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Adv Skin Wound Care"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Pemphigus vulgaris (PV) is a rare, but potentially life-threatening (5%-30%) intraepidermal blistering disease with a mean onset age between 40 and 60 years. Disease onset typically begins in the oral mucosa prior to spreading to the skin. Classic PV is characterized by fragile flaccid blisters on normal or erythematous skin that have a tendency to break and form erosions. Diagnosis of PV can be supported by direct immunofluorescence detection of immunoglobulin G and C3 deposits on the surface of keratinocytes and immunoserology studies to detect anti-desmoglein 1\/3 autoantibodies. Systemic corticosteroids are the mainstay of PV treatment and are often combined with other immunosuppressive adjuvants to improve remission rates. This review focuses on the clinical presentation, risk factors, and treatment options for PV.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>GENERAL PURPOSE<\/jats:title>\n                    <jats:p>To review the clinical presentation, diagnostic evaluation, and management approaches for pemphigus vulgaris (PV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TARGET AUDIENCE<\/jats:title>\n                    <jats:p>This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and registered nurses with an interest in skin and wound care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LEARNING OBJECTIVES\/OUTCOMES<\/jats:title>\n                    <jats:p>After participating in this educational activity, the learner will: 1. Summarize the clinical manifestations associated with PV. 2. Evaluate risk factors associated with PV. 3. Explain evidence-based diagnostic and treatment options for PV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/asw.0000000000000307","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:05:39Z","timestamp":1743782739000},"page":"232-238","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pemphigus Vulgaris: Clinical Aspects and Treatments"],"prefix":"10.1097","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-095X","authenticated-orcid":false,"given":"Ryan S. Q.","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Gary","family":"Sibbald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"4","key":"bib1-20250520","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000530121","article-title":"The global incidence rate of pemphigus vulgaris: a systematic review and meta-analysis","volume":"239","year":"2023","journal-title":"Dermatology"},{"issue":"1","key":"bib2-20250520","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41702-017-0008-1","article-title":"A brief review of pemphigus vulgaris","volume":"1","year":"2017","journal-title":"Biomed Dermatol"},{"issue":"5","key":"bib3-20250520","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2340\/00015555-2611","article-title":"Mortality and cause of death in patients with pemphigus","volume":"97","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"bib4-20250520","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2230.2011.04092.x","article-title":"The pathogenic role of autoantibodies in pemphigus vulgaris","volume":"36","year":"2011","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"bib5-20250520","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/1346-8138.16875","article-title":"Psychological morbidity in patients with pemphigus and its clinicodemographic risk factor: a comparative study","volume":"50","year":"2023","journal-title":"J Dermatol"},{"issue":"2","key":"bib6-20250520","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00403-017-1790-8","article-title":"Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus","volume":"310","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"4855","key":"bib7-20250520","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1126\/science.3368786","article-title":"A molecular basis for MHC class II-associated autoimmunity","volume":"240","year":"1988","journal-title":"Science"},{"issue":"3","key":"bib9-20250520","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"2","key":"bib10-20250520","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.iac.2012.04.003","article-title":"Diagnosis and clinical features of pemphigus vulgaris","volume":"32","year":"2012","journal-title":"Immunol Allergy Clin North Am"},{"issue":"9","key":"bib13-20250520","first-page":"1077","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"bib14-20250520","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"bib15-20250520","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1590\/abd1806-4841.20199165","article-title":"Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview","volume":"94","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"4","key":"bib16-20250520","first-page":"367","article-title":"Oral pemphigus vulgaris: case report","volume":"25","year":"2015","journal-title":"Ethiop J Health Sci"},{"issue":"10","key":"bib17-20250520","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1468-3083.2010.03610.x","article-title":"Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris","volume":"24","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"bib18-20250520","first-page":"42","article-title":"Randomized trial of tacrolimus 0.1% ointment versus triamcinolone acetonide 0.1% paste in the treatment of oral pemphigus vulgaris","volume":"15","year":"2012","journal-title":"Iranian J Dermatol"},{"issue":"5","key":"bib19-20250520","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-4362.1990.tb04765.x","article-title":"Pemphigus therapy with oral prednisolone regimens. A 5-year study","volume":"29","year":"1990","journal-title":"Int J Dermatol"},{"issue":"10","key":"bib20-20250520","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1468-3083.2012.04717.x","article-title":"Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris","volume":"27","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"bib21-20250520","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"10083","key":"bib22-20250520","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"bib23-20250520","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"bib24-20250520","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1067\/S0190-9622(03)00859-4","article-title":"Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus","volume":"49","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"bib25-20250520","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1684\/ejd.2011.1611","article-title":"Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris","volume":"22","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"1","key":"bib26-20250520","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1038\/s41598-022-11387-2","article-title":"A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris","volume":"12","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"bib27-20250520","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2133.2009.09208.x","article-title":"The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study","volume":"161","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"bib28-20250520","first-page":"25","article-title":"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris","volume":"144","year":"2008","journal-title":"Arch Dermatol"},{"issue":"3","key":"bib29-20250520","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2230.1994.tb01168.x","article-title":"Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy","volume":"19","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"1 Pt 1","key":"bib30-20250520","first-page":"85","article-title":"The use of chlorambucil with prednisone in the treatment of pemphigus","volume":"42","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"bib31-20250520","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.transci.2010.10.006","article-title":"Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy","volume":"43","year":"2010","journal-title":"Transfus Apher Sci"}],"container-title":["Advances in Skin &amp; Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ASW.0000000000000307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:00:46Z","timestamp":1747753246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ASW.0000000000000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/asw.0000000000000307","relation":{},"ISSN":["1538-8654","1527-7941"],"issn-type":[{"value":"1538-8654","type":"electronic"},{"value":"1527-7941","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,4]]}}}